Guangji Pharmaceutical: Obtained the drug registration certificate for Methylcobalamin tablets

K-LinePoet · 2026-02-26T11:03:33+00:00

Guangji Pharmaceutical received the drug registration certificate for Methylcobalamin Tablets approved by the National Medical Products Administration, which are mainly used to treat peripheral neuropathy. This marks an important advancement in the company's product layout in the relevant field.

K-LinePoet

2026-02-26 11:03:33

Abstract generation in progress

Guangji Pharmaceutical announced that it has recently received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration for Methylcobalamin Tablets. The generic name of the drug is Methylcobalamin Tablets, with acceptance number CYHS2402791, certificate number 2026S00402, dosage form tablets, packaging specifications of 10 tablets per sheet × 2 sheets per box, registration category Class 4 chemical drug, drug registration standard number YBH01362026, and approval number GuoYaoZhunZi H20263341. Methylcobalamin Tablets are mainly used for the treatment of peripheral neuropathy. The approval of this “Drug Registration Certificate” marks an important progress in the company’s product layout in the field of peripheral nerve disease treatment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.